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ABSTRACT 
Objective: The main motive is to develop proniosomes loaded orabase for enhanced permeation and prolonged release of aceclofenac for oro 
dental conditions. 
Methods: Various aceclofenac (ACL) proniosomal gels were formulated employing various surfactants, span 60 was superior and significant for 
loading into orabase. The formulations were scrutinized for entrapment efficiency, optical microscopy, in vitro diffusion and release studies, 
mucoadhesive strength, ex-vivo permeation studies and drug-excipient interactions were determined by FTIR spectroscopy.  
Results: Considering best entrapment efficiency with span 60 (97.60±1.85) and optimum vesicle shape, along with prolonged drug permeation 
(45% for 24 h) the formulation F(ACL)1 was selected and optimized for loading into orabase. The F(ACL)1 loaded orabase exhibited significant 
prolonged release over 14 h, and permeation profiles exhibited nearly two-fold increased flux in comparison with control. Good mucoadhesive 
strength was observed for proniosomal orabase 6370 dynes/cm2
Conclusion: Orabase can be an effective carrier for proniosomes with enhanced permeation and prolonged release for oro-dental conditions. 
. No evidence of incompatibility amongst formulation components from FTIR 
studies. SEM images revealed the particle size range from 136 µm to 236 µm for proniosomal orabase. 
Keywords: Aceclofenac, Oro-dental pain, proniosomal gel, Orabase, Entrapment efficiency, Prolonged release 




Patients with oro-dental aliments often suffer awful pain due to 
significant tissue damage and inflammation. The effective analgesic 
screening and dosage regimen depend on the nature and intensity of 
pain the patient experience. Oral cavities are the chief complaint about a 
toothache, nonsteroidal anti-inflammatory drugs (NSAIDs) effectively 
mitigate acute and chronic dental, tissues and other adjacent structures 
[1]. With the advancements in understanding, pain pathophysiology 
novel strategies for drug delivery assessed to alleviate pain at peripheral 
sites to enhance the therapeutic benefit of the drug [2]. 
ACL is an NSAID and exhibits potent analgesic activity, effective in 
the treatment of painful inflammatory conditions, mostly 
administered orally. It is broadly prescribed for conditions 
rheumatoid arthritis, osteoarthritis, acute lumbago, and dental pain 
and oral dental ailments. Gastrointestinal disturbances raise 
concerns to post oral ACL administration. Hence, a better strategy 
with a significant scale of safety is essential to overcome such 
systemic side-effects. One such strategy, designing the delivery 
system with localized action at the site of ailment. Thereby, lowers 
systemic disturbances and improves the efficiency of the drug by 
potentiating drug concentration at the site of inflammation with low 
dose relative to conventional oral administration hence increases 
patient compliance. 
Proniosomes are dehydrated preparations employing suitable non-
ionic surfactants and carrier, the preparation further yields 
niosomes on hydration with water [3]. Niosomes are proven to be 
best carriers for drug targeting, relatively less toxic, stable, and 
economical and better permeation than liposomes.  
Ora base is an effective mucoadhesive base effectively employed as a 
drug carrier, considered as a hydrophobic gel or dental paste. The aim of 
the present investigation was to achieve the prolonged release of ACL by 
loading in proniosome vesicles and improve its retention time at the 
particular site of action by incorporating drug loaded proniosomes into 
orabase this significantly reduces dosage frequency hence increase 
patient compliance.  
MATERIALS AND METHODS 
Materials 
ACL was purchased from yarrow chem products (Mumbai, India), span 
40 (sorbitan monopalmitate) and span 60 (sorbitan monostearate), 
were purchased from loba chemie pvt. ltd. (Mumbai, India), span 20 
(sorbitan monolaurate) and span 80 (sorbitan monooleate) were 
purchased from molychem (Mumbai, India). Cholesterol was purchased 
from finar chemicals pvt. Ltd (Ahmedabad, India) and soya lecithin were 
obtained from sigma chemicals limited (Hyderabad, India).  
Methods 
Preparation of aceclofenac proniosomal gel 
ACL loaded proniosomal gel was formulated employing coacervation 
phase separation method [4, 5]. The required measures of surfactant, 
lecithin and c holesterol were dissolved in alcohol in a beaker as 
shown in (table 1). Contents were stirred uniformly using glass rod, 
further introduced into water bath shaker (REMI) to warm the 
ingredients (60-70 ℃) for about five minutes for complete 
solubilization. Consequently, aqueous buffer pH 7.4 was added to the 
preparation, with gentle warming yielded proniosomal gel on cooling. 
 
Table 1: Composition of the proniosomal formulation of Aceclofenac 








pH 7.4 buffer 
(ml) 
1 F (ACL) 1 Span 60 10 468 468 52 1.6 
2 F (ACL) 2 Span 40 10 468 468 52 1.6 
3 F (ACL) 3 Span 20 10 468 468 52 1.6 
4 F (ACL) 4 Span 80 10 468 468 52 1.6 
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Entrapment efficiency  
Proniosomal formulations (0.2g) after reconstitution with sufficient 
aqueous buffer (pH 7.4) in suitable centrifuge tube were executed 
for centrifugation using a cooling centrifuge at 3500 rpm for about 1 
h at 4℃ [6]. The clear and distinct supernatant was collected 
carefully to separate unentrapped ACL, and the sediment was then 
treated with ethanol (1 ml) to lyse the vesicles and diluted with 
ethanol respectively, and absorbances were determined 
spectrophotometrically at 275 nm. The entrapment efficiency was 
determined using the following equation, 
% E. E = 1 −  
( Unentrapped drug)
(Total drug)
×  100 
Optical microscopy 
The preparation with clear liquid crystalline state yielded niosomal 
suspension upon hydration; the same was mounted on a glass slide 
and examined for vesicles using a compound microscope under 
100X magnification, magnified images were captured.  
In vitro diffusion 
In vitro release studies were performed for the preparations using 
Franz diffusion cell. Dialysis membrane was positioned between 
receptor and donor compartments. An equivalent dose of ACL 
preparation was introduced on the membrane. Receptor 
compartment was charged with pH 7.4 buffer (15 ml). Cells were 
conditioned at 37±5℃ with stirring at 500 rpm. At predetermined 
time periods aliquots were withdrawn from the receptor 
compartment, respectively and the same was replenished with fresh 
buffer. The samples were analysed spectrophotometrically. 
Preparation of aceclofenac proniosomal orabase 
Required equivalent quantities of gelatin, pectin, sodium 
carboxymethylcellulose, polyethylene glycol, and liquid paraffin 
were blended and triturated in optimum ratios for obtaining a 
smooth orabase in a mortar and pestle. Further desired amount of 
aceclofenac loaded proniosomal gel was incorporated with uniform 
stirring until homogeneity was achieved.  
Preparation of aceclofenac orabase 
Gelatin, pectin, sodium carboxymethylcellulose, polyethylene glycol, 
and liquid paraffin were blended and triturated in optimum ratios 
for obtaining orabase in a mortar and pestle. Further equivalent 
amount of ACL was incorporated with uniform stirring until 
homogeneity was achieved.  
In vitro release studies 
ACL proniosomal gel loaded orabase and drug orabase was 
characterized for its release employing membrane diffusion technique 
[7]. The preparation equivalent to 60 mg aceclofenac was diluted with 1 
ml of the buffer, introduced to the lower end of the glass cylinder on 
preconditioned dialysis membrane. The cylinder was maintained at 30 
rpm with the membrane end being submerged in the dissolution jars. 
The dissolution medium phosphate buffer pH 7.4 was maintained at 
37±5℃. The suitable volume of the sample was withdrawn at 
predetermined time periods; the same was replenished with fresh buffer 
and samples were assayed spectrophotometrically [8].  
Determination of mucoadhesive strength of the proniosomal 
orabase formulation 
The mucoadhesive strength of aceclofenac loaded proniosomal 
orabase formulation was determined by measuring the potency 
necessary for detaching the preparation from oral goat mucosa using 
dispensing balance [9]. Equal pieces (2.5×2.5 cm), cut from the goat 
oral mucosal membranes, [10] were horizontally fixed to the upper 
stage of the dispensing balance keeping the mucosal side out. 
Proniosomal preparation (0.5 g) was positioned on the lower steel 
stage enabling the sample surface to adjoin mucosal membrane 
attached to the upper stage [11, 12]. The sample was placed adjacent 
to the mucosal membrane for 5 min. Into the other pan of dispensing 
balance water was added in dropwise manner until the mucosal 
membrane extricates from the gel sample. The mucoadhesive 
strength was measured in dyne/cm2
Where m is the weight of water added to the balance in gram, g is 
acceleration due to gravity (980 cm/s
. The minimum amount of water 
required to detach the formulation from the oral mucosa surface 
was determined by using the following equation [13] 




2), and A is an area of tissue 
exposed in cm2
Ex vivo permeation studies 
. 
Proniosomal orabase permeation against buccal mucosa was 
determined employing altered Franz diffusion cell. The buccal mucosal 
membrane of goat pre-conditioned was placed in between donor and 
receptor compartments with the mucosal side facing the gel sample in 
the donor compartment. An equivalent amount of proniosomal orabase 
was introduced to the donor compartment, and subsequently, 50 ml of 
phosphate buffer filled in the receptor compartment maintained at 
37±5℃ and stirred at 50 rpm. A suitable volume of sample was 
withdrawn at predetermined time periods, the same was replenished 
with fresh buffer and samples were assayed spectrophotometrically. The 
permeability coefficient calculated [14] 
Kp =  Jss Cdonar⁄  
The flux of drug was calculated using Jss
The permeation coefficient of the drug was calculated using formula 
Kp =  flux initial conc. of drug in donar chamber�  
 formula i.e., 
Jss =  
amount of drug permeated
time × area of membrane�  
Determination of drug deposited into oral mucosa 
The amount of the aceclofenac retained in the buccal mucosa 
membrane was estimated by detaching the buccal mucosa 
membrane followed by diffusion studies rinsed with distilled water 
to washout formulation adhered to the membrane. The membrane 
was shredded into small pieces and then sonicated in 10 ml ethanol 
for 30 min to leach out the drug. Then the sonicated ethanol was 
assayed spectrophotometrically for estimating the amount of ACL 
remained deposited in the buccal mucosa. 
Optical microscopy 
The proniosomal orabase and drug orabase was placed on a glass 
slide and observed for vesicles using a compound microscope under 
100X magnification; magnified images were captured. 
Drug-excipient compatibility studies 
An efficient formulation emphasises on physiochemical and biological 
characteristics of active and excipient employed for product 
development. Hence signifies compatibility of active and excipients to 
yield the stable and safe product. Fourier transforms infrared 
spectroscopy is a significant analytical technique employed to study 
chemical interactions within active and excipients in the formulations. 
Active and excipient were mixed extensively with potassium bromide. 
The samples were introduced into diffuse reflectance sampler, and 
subsequent spectrums were recorded in wavelength region 4000-400 
cm-1
Scanning electron microscopy (SEM) 
 in FT-IR.  
The particle size of proniosomal orabase is a factor of prime importance. 
The surface morphology and size distribution of proniosomal orabase 
were studied by SEM. Proniosomal gel was applied on double-sided tape 
attached on aluminium stubs. The stubs were introduced to the vacuum 
chamber of SEM (XL 30 ESEM with EDAX, Philips, Netherlands). The 
samples were screened for morphological characteristics using a 
gaseous secondary electron detector (working pressure of 0.8 torr, 
acceleration voltage-30.00 KV) XL 30, (Philips, Netherlands) [15]. 
RESULTS AND DISCUSSION 
To obtain appropriate vesicular formulation for delivery of ACL in 
the oral cavity for dental pain management, various proniosomal 
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systems were formulated employing cholesterol and lecithin as 
membrane stabilizers along with a range of non-ionic surfactants, 
spans (20, 40, 60, and 80) proniosomal gel systems were formulated 
for effective incorporation broad range of actives. Non-ionic 
surfactants employed non-toxic and compatible with the biological 
system. The systems were formulated by blending vesicular 
components with alcohol and aqueous phase yielding concentrated a 
liquid crystalline system that produces niosomal dispersion 
instantaneously on exposure to saliva in the oral cavity. 
Formulations pertaining to span 60 and 40 evinced semisolid 
consistency, whereas span 20 and 80 exhibited liquid consistency. 
Entrapment efficiency  
For a better pharmaceutical perspective, entrapment efficiency is a 
consequential parameter for collating various proniosomal 
formulations. ACL is incorporated into the vesicles. The 
Formulation comprising span 60 exhibited highest entrapment 
efficiency over other spans, span 80 showed minimal 
entrapment efficiency. Observed variation with entrapment 
efficiencies of different surfactants is the consequence of diverse 
structure and length of alkyl chain used as surfactants [16]. The 
entrapment efficiencies of the respective formulation are 
presented in (fig. 1). 
Optical microscopy 
The size of the formed vesicles has a major contribution towards 
in vivo fate. From (fig. 2) it is observed that the shape of 
proniosomal (F (ACL)1-F(ACL)4) formulations exhibited, following 








Fig. 2: Optical microscopic images of proniosomal formulations A) F1(Span60) B) F2(Span40) C) F3(Span20) D) F4(Span80) at 100X 
magnification 
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In vitro diffusion 
Amongst the different formulations, F(ACL)1 showed 45% drug 
release for 24h diffusion as shown (fig. 3). Consequently, 
formulation F(ACL)1 exhibited higher diffusion as compared to 
F(ACL)2-F(ACL)4 respectively. Commonly the release profiles of the 
proniosomal systems predominantly depended on hydrophobic 
lipophilic balance (HLB) value besides the alkyl chain length. 
  
 
Fig. 3: In vitro diffusion profiles of proniosomal formulations data expressed mean±SD (n= 𝟑𝟑) 
 
Aceclofenac proniosomal orabase 
From the in vitro diffusion profile, with F(ACL)1 showing prominent 
profile compared to F(ACL)2-F(ACL)4 respectively, consequently 
F(ACL)1 was incorporated into orabase, enabling increased 
retention time within oral mucosa.  
Aceclofenac orabase 
ACL was directly incorporated into orabase as a control for 
comparison with the proniosomal orabase.  
In vitro release 
Release profiles comprehend the efficiency in the delivery of the 
drug by the proposed system. Complete release from ACL loaded 
orabase was achieved within 3 h which verify the aptitude of the 
drug to permeate through the membrane. It was learned the 
release of ACL proniosome system exhibited significantly lower 
release rates compared to control. This specifies that the lipid 
bilayer of niosomes limits drug release. An interrelation between 
the entrapment efficiency and the drug release was scrutinized. 
The higher proportion of drug entrapped within vesicles, the 
slower the release profile. The release from proniosomal orabase 
was slow and spread over more than 14 h, compared to ACL 
orabase with a complete release within a few hours. Significantly 
the release of the proniosomal orabase formulation was 
protracted than that of ACL loaded orabase. The release profiles 




Fig. 4: In vitro release profiles of proniosomal and drug orabase data expressed mean±SD (n= 𝟑𝟑) 
 
Mucoadhesive strength of the proniosomal orabase formulation 
For delivery of a therapeutic agent from the formulation system 
through oral mucosa should attribute simple application and sustained 
retention for establishing clinical efficiency. Even though proniosomal 
system features significant placement for oral mucosa, but the 
therapeutic effect is limited due to poor retention on the epithelium. 
To handle this impediment besides establishing better retention the 
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formulation system was incorporated into the orabase mucoadhesive 
gel. Mucoadhesive strength can be related to fracture theory. The 
adhesive bond between systems is linked to the force needed to detach 
surfaces from each other. This theory is associated with the force 
essential for a polymer to separate from the mucus towards their 
adhesive bond strength. Consequently, the mucoadhesive strength in 
terms of detachment force of the system prepared by incorporating 
proniosomal gel in orabase and was examined. Proniosome 
incorporated orabase exhibited significantly increased in 
mucoadhesive force compared plain proniosome. Besides the weight 
applied to detach the mucous from the proniosomal gel mucoadhesive 
strength was found to be 6370dynes/cm2
Post local administration in the oral cavity upon exposure to saliva, 
proniosomal gels transform into niosomal vesicles. Formed vesicles 
increase the penetration of stagnant drug molecules over the 
mucosal membrane. By adsorption and integration of intact vesicles 
with mucosal membrane enhances permeation of lipophilic 
molecules besides enhancing thermodynamic activity gradient at the 
membrane. From the release profiles (fig. 5) it was evident that after 
24h percentage drug released for proniosomal orabase and ACL 
loaded orabase were determined to be 36.6% and 21.6% 
respectively with permeation coefficient of 10.397 cm
. 
Ex vivo permeation studies 
2/h and 3.270 
cm2/h. exhibited flux of 230 µg/cm2/h and 110µg/cm2
  
/h for 
proniosomal orabase and aceclofenac loaded orabase respectively. 
Comprehensively the permeation of ACL proniosomal orabase 
systems exhibited significantly enhanced and higher permeation 
compared to the control, recommending interaction of vesicles with 
mucosal membrane. The enhanced permeation of the prepared 
system is attributed to the existence of non-ionic surfactants besides 
formation of niosomal vesicles upon hydration. 
 
Fig. 5: Ex-vivo permeation profiles of proniosomal and drug orabase data expressed mean±SD (n= 𝟑𝟑) 
 
Drug deposited in oral mucosa  
Selected proniosomal orabase formulation exhibited 68.26% 
retention in the oral mucosa. The formulation showed significant 
deposition within the oral mucosal layer when compared to control 
preparation. This reveals potential aspects of these intact niosomes 
to overcome the epithelial barrier of the oral mucosa and enhance 
concentrate within mucosal layers.  
Optical microscopy 
From (fig. 6) it is observed that the shape of proniosomal orabase 
formulation exhibited spherical morphology at 100X magnification. 
The proniosomal orabase formulation system exhibited abundant 
vesicle formation in contrast to drug orabase. 
Drug-excipient compatibility studies 
FTIR studies were performed for ACL pure drug, proniosomal orabase 
and drug orabase and are in shown in (table 2). From the results, it was 
evident that there is no noticeable change in the peak of the spectrums of 
drug and excipients mixture. In recent observation there was no 
significant variation in dosage stability and used excipients was found. 
Individuality peaks of ACL were clearly established without any 
interaction of excipients used in proniosomal orabase formulation and 
drug orabase formulation as shown in the (fig. 7, 8, 9). 
  
 
Fig. 6: Optical microscopic images of proniosomal and drug orabase formulations A) Proniosomal Orabase B) Drug orabase at 100X 
magnification 
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Table 2: FTIR bands of aceclofenac, proniosomal orabase and drug orabase 
Functional group IR band of ACL pure drug (cm-1 IR band of proniosomal orabase (cm) -1 IR band of drug orabase (cm) -1) 
Alkane (CH2-CH2 2934.54 ) 2919.68 2919.60 
Secondary Amine (NH) 661.97 615.31 682.14 
Carboxylic Acid (COOH) 1716.78 1712.70 1374.77 
Ester (COOR) 1770.13 1712.70 1748.19 
Aromatic ring stretching (C=C-C) 1578.84 1459.43 1095.93 
 
 
Fig. 7: FTIR Aceclofenac pure drug 
 
 
Fig. 8: FTIR Proniosomal orabase 
 
 
Fig. 9: FTIR drug orabase 
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Scanning electron microscopy (SEM) 
As depicted in the SEM images revealed the well identified spherical 
morphology of proniosomal orabase, post hydration prepared 
employing span 60, increased vesicle size greatly lowers mucosal 
penetration. Considering the aforementioned size distribution was 
examined, and the formulation exhibited particle size ranges from 136 




Fig. 10: SEM image of proniosomal orabase 
 
CONCLUSION 
There have been enormous efforts put in the development of novel 
routes for NSAIDs administration to deliver adaptive treatments for 
patients ailing with dental pain with better safety margin without 
losing the efficiency for analgesia and pain management.  
Endeavouring effort was made in preparing much safer and an 
alternative for oral route. Considering proniosomal gels in which 
aceclofenac was successfully entrapped with high efficiency into 
vesicles. Proniosomal gel formulation F(ACL)1, considered optimal 
formulation with EE% (97.60±1.85 %) post reconstitution. As a 
result, the optimal formula was further incorporated into orabase 
with desirable mucoadhesive behaviour essential to achieve 
increased retention for effective pain management. The formula 
exhibited significant permeation with two-fold increased flux and 
sustained for longer periods compared to the aceclofenac control at 
the same dose level. Hence, orabase loaded with proniosomal gels 
may be a promising carrier for NSAIDs in dental pain management 
with their intact vesicles and safety aspects for local action for 
longer periods with simple preparation technique.  
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